Oramed Pharmaceuticals Inc. (ORMP.TA)
ILA 843.2
(-0.01%)
ILA 843.2
(-0.01%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2022 | 568.82 Million USD | 38.71% |
| 2021 | 410.07 Million USD | 174.12% |
| 2020 | 149.59 Million USD | 22.23% |
| 2019 | 122.38 Million USD | -28.26% |
| 2018 | 170.6 Million USD | 22.87% |
| 2017 | 138.84 Million USD | -14.3% |
| 2016 | 162.01 Million USD | 56.26% |
| 2015 | 103.68 Million USD | 33.2% |
| 2014 | 77.83 Million USD | 148.22% |
| 2013 | 31.35 Million USD | 47.55% |
| 2012 | 21.25 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 Q3 | 882.14 Million USD | 51.93% |
| 2023 Q2 | 580.63 Million USD | 0.81% |
| 2023 Q1 | 575.97 Million USD | 1.26% |
| 2022 Q2 | 567.43 Million USD | 3.0% |
| 2022 Q1 | 550.92 Million USD | -0.16% |
| 2022 Q3 | 585.97 Million USD | 3.27% |
| 2022 Q4 | 568.82 Million USD | -2.93% |
| 2022 FY | 568.82 Million USD | 38.71% |
| 2021 Q2 | 261.47 Million ILA | 28.02% |
| 2021 Q1 | 204.25 Million USD | 50.84% |
| 2021 FY | 410.07 Million USD | 174.12% |
| 2021 Q3 | 410.07 Million USD | 56.83% |
| 2021 Q4 | 551.82 Million USD | 34.57% |
| 2020 Q2 | 162.06 Million USD | 56.27% |
| 2020 FY | 149.59 Million USD | 22.23% |
| 2020 Q1 | 103.71 Million USD | -4.19% |
| 2020 Q3 | 149.7 Million USD | -7.63% |
| 2020 Q4 | 135.4 Million USD | -9.55% |
| 2019 Q4 | 108.24 Million USD | -11.64% |
| 2019 Q3 | 122.51 Million USD | -9.72% |
| 2019 FY | 122.38 Million USD | -28.26% |
| 2019 Q2 | 135.7 Million USD | -10.45% |
| 2019 Q1 | 151.53 Million USD | -6.51% |
| 2018 Q1 | 133.03 Million USD | -8.36% |
| 2018 Q2 | 123.55 Million USD | -7.13% |
| 2018 FY | 170.6 Million USD | 22.87% |
| 2018 Q4 | 162.07 Million USD | -5.15% |
| 2018 Q3 | 170.88 Million USD | 38.3% |
| 2017 Q3 | 138.74 Million USD | -1.49% |
| 2017 Q2 | 140.84 Million USD | -7.53% |
| 2017 Q1 | 152.31 Million USD | -11.51% |
| 2017 FY | 138.84 Million USD | -14.3% |
| 2017 Q4 | 145.17 Million USD | 4.64% |
| 2016 Q1 | 149.96 Million USD | 62.14% |
| 2016 FY | 162.01 Million USD | 56.26% |
| 2016 Q4 | 172.11 Million USD | 6.41% |
| 2016 Q3 | 161.75 Million USD | 15.6% |
| 2016 Q2 | 139.92 Million USD | -6.69% |
| 2015 FY | 103.68 Million USD | 33.2% |
| 2015 Q3 | 103.61 Million USD | 20.9% |
| 2015 Q1 | 91.53 Million USD | -4.35% |
| 2015 Q2 | 85.69 Million USD | -6.38% |
| 2015 Q4 | 92.48 Million USD | -10.73% |
| 2014 Q3 | 77.83 Million USD | -0.36% |
| 2014 Q4 | 95.7 Million USD | 22.95% |
| 2014 FY | 77.83 Million USD | 148.22% |
| 2014 Q2 | 78.11 Million USD | -5.51% |
| 2014 Q1 | 82.67 Million USD | 193.05% |
| 2013 Q4 | 28.21 Million USD | -10.04% |
| 2013 Q3 | 31.35 Million USD | 75.31% |
| 2013 Q1 | 22.11 Million USD | -15.01% |
| 2013 FY | 31.35 Million USD | 47.55% |
| 2013 Q2 | 17.88 Million USD | -19.11% |
| 2012 Q3 | 21.25 Million USD | 0.0% |
| 2012 FY | 21.25 Million USD | 0.0% |
| 2012 Q4 | 26.01 Million USD | 22.42% |
| Name | Total Assets | Total Assets Difference |
|---|